Navigation Links
Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
Date:9/18/2007

tements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007 and quarterly report on form 10-Q for the period ended June 30, 2007.

References

1. Joos GF, Schelfhout VJ, Kanniess F et al. Bronchodilator effects of

aclidinium bromide, a novel long-acting anticholinergic, in COPD

patients: a phase II study. European Respiratory Society (ERS) Annual

Congress, September 2007. Poster.

2. Schelfhout VJ, Joos GF, Gil EG et al. Bronchodilator/bronchoprotective

effects of aclidinium bromide, a novel long-acting anticholinergic: a

phase I study. European Respiratory Society (ERS) Annual Congress,

September 2007. Poster.

3. Gavalda A, Miralpeix M, Ramos I et al. Aclidinium bromide, a novel

muscarinic receptor antagonist combining long residence at M3 receptors

and rapid plasma clearance. European Respiratory Society (ERS) Annual

Congress, September 2007. Poster.

4. Miralpeix M, Gavalda A, Morcillo E et al. Assessment of the potency and

duration of action of aclidinium bromide in guinea pig isolated trachea

in vitro. European Respiratory Society (ERS) Annual Congress, September

2007. Poster.

5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy

for the diagnosis, management, and prevention of chronic obstructive

pulmonary disease; MCR Vision, Inc.; 2006

6. CDC, http://www.cdc.gov/nceh/airpollution/copd/copdfaq.htm, accessed

Sept
'/>"/>

SOURCE Forest Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Calif. , Aug. 3, 2015  Isis ... today announced a strategic collaboration to discover and ... diseases. The new collaboration builds on a broad ... AstraZeneca,s strategic approach in these therapeutic areas using ... to extend use of its antisense technology to ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. ... pivotal TELESTAR Phase 3 clinical trial met its ... etiprate in treating cancer patients with carcinoid syndrome ... standard of care. Telotristat etiprate was discovered using ... and is the company,s first discovery to complete ...
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 /PRNewswire/ ... needs of customers who are increasingly mobile, increasingly connected, ... support a growing variety of customer interaction channels and ... of technology, including social media. According ... of the over the counter (OTC) segment in a ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to ... University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative ... Africa. , A cooperative agreement awarded by the U.S. Agency for International ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato ... new program “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive ... healthcare organizations with access to the tactics, techniques and practices required to design ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... - When given alongside radiation therapy for head and ... to reduce the debilitating side effect of xerostomia, according ... Anderson Cancer Center and Fudan University Shanghai Cancer Center. ... , reported findings from the first randomized controlled trial ...
... press release is available in French . , ... metastasis has been identified by a team of researchers led by ... Health Centre (RI-MUHC). Complications in breast cancer patients are commonly caused ... of the body, most often to the bones and lungs. These ...
... Norwegians, the investigators found that alcohol consumption was associated ... from coronary artery disease. For men, the fully ... CI 0.39 - 0.69) when comparing subjects reporting more ... or rarely drinking; for women, it was 0.62 (0.3-.23). ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... , THURSDAY, Nov. 10 (HealthDay News) -- ,Heavy ... according to a new study. It also confirmed ... and schizophrenia. Methamphetamine and other amphetamine-type stimulants are ... worldwide. In this study, researchers at the Centre ...
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay ... livers are typically subject to a mandatory six-month "dry-out" ... Unfortunately, many of the sickest of these patients fail ... that earlier transplants can dramatically improve survival odds in ...
Cached Medicine News:Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 3Health News:New target identified to stop the spread of breast cancer 2Health News:Flexible rack systems sort molecules 2Health News:Heavy Meth Use Linked to Schizophrenia 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 3
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
... - 200: 200V, .01-2A. 300: 300V, 4-400mA. ... Select constant voltage or constant current ... gels. - Compact, lightweight and stackable. - ... - Ideal for DNA, RNA and protein ...
... The MAX POWER Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
Medicine Products: